吸入裂纹可卡因通过降低乙胆酶活性增加了发作易感性
Cibelle de Melo Bastos Cavalcante1, Kellysson Bruno Oliveira1, Fernanda Maria Araújo de Souza1
1Department of Physiology, Institute of Biological Science and Health of Federal University of Alagoas, Maceió, Alagoas, Brazil.
Epilepsy & behavior : E&B
|May 18, 2024
概括
裂可卡因吸入通过抑制乙胆酶 (AChE) 来降低大鼠的发作值. 这种神经毒性效应与可卡因裂有关.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 裂可卡因是一种强大的兴奋剂药物,以其高成潜力而闻名.
- 胆固醇系统与可卡因诱导的神经毒性有关.
- 裂可卡因的使用与行为变化有关,包括过度活跃和减少发作值.
研究的目的:
- 研究可卡因暴露对乙胆化酶 (AChE) 活性,活性氧物种 (ROS) 水平,发作值和大鼠行为的影响.
- 确定ACHE抑制在可卡因可卡因引起的神经毒性和的作用.
主要方法:
- 给大鼠注射了海马内皮洛卡 (H-PILO),然后是可卡因 (H-PILO + CRACK) 或仅可卡因 (CRACK).
- 测量了乙胆酶 (AChE) 活性,活性氧物种 (ROS) 水平和发作值.
- 进行了行为测试,包括运动活动和摄入水和糖.
- 评估了短期记忆的巩固.
主要成果:
- 暴露于H-PILO + CRACK的动物表现出边缘性的严重程度和频率增加.
- 暴露于裂可卡因 (CRACK和H-PILO + CRACK) 显著降低了ACHE活动.
- 在所有实验组中,ROS水平保持不变.
- 裂可卡因增加了垂直运动活动,但没有影响水或糖的摄入量.
- 短期记忆的巩固没有受到治疗的改变.
结论:
- 裂可卡因吸入降低了先前用皮洛卡治疗的老鼠的发作值,主要是通过抑制ACHE.
- 这些发现凸显了可卡因对中枢神经系统的神经毒性潜力,特别是在方面.
- 结果为开发策略提供了见解,以减轻与可卡因和可卡因使用有关的神经损害.
更多相关视频
相关概念视频
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
185
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
185
Depolarizing Blockers: Pharmocokinetics
319
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
319
Anticholinesterase Agents: Poisoning and Treatment
848
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
848
Stimulants
187
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
187
Antiepileptic Drugs: GABAergic Pathway Potentiators
385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286


